HIV Pipeline
← 실적 발표
01
02
03
04 05 06
톤
A1 A2 A3
GILD
FY2026 Q1
상향
Gilead Sciences, Inc. 실적 발표
Buzzberg 분석
HIV franchise positioned for durable growth with seven potential launches by 2033
Gilead reported a strong Q1 2026, led by HIV and its new PrEP drug Yes2Go, whose full-year sales guidance was raised to $1 billion. Management also provided an update on its recently closed Arcelix acquisition (anito-cel) and the pending Tubulis ADC deal, emphasizing a robust pipeline and the ability to absorb the heavy acquisition costs. Total product sales: $6.9B (+5% YoY), with HIV franchise at $5.0B (+10% YoY).
Buzzberg 분석 HIV franchise positioned for durable growth with seven potential launches by 2033 Gilead reported a strong Q1 2026, led by HIV and its new PrEP drug Yes2Go, whose full-year sales guidance was raised to $1 billion. Management also provided an update on its recently closed Arcelix acquisition (anito-cel) and the pending Tubulis ADC deal, emphasizing a robust pipeline and the ability to absorb the heavy acquisition costs. Total product sales: $6.9B (+5% YoY), with HIV franchise at $5.0B (+10% YoY). 전체 분석 보기분석 접기
Gilead reported a strong Q1 2026, led by HIV and its new PrEP drug Yes2Go, whose full-year sales guidance was raised to $1 billion. Management also provided an update on its recently closed Arcelix acquisition (anito-cel) and the pending Tubulis ADC deal, emphasizing a robust pipeline and the ability to absorb the heavy acquisition costs. Total product sales: $6.9B (+5% YoY), with HIV franchise at $5.0B (+10% YoY).
- Yes2Go sales: $166M in Q1 (up 72% sequential), full-year 2026 guidance raised to $1B from $800M.
- 2026 total product sales guidance raised by $400M to $30.0-30.4B; non-GAAP EPS is a loss of $1.05-$0.65 due to ~$11.5B in acquired IPR&D charges.
- Acquisition of Arcelix closed April 28th; anito-cel PDUFA is December 2026, with revenue expected to begin early 2027.
HIV 매출$5B보고값
매출$6.96B-12% 전분기 대비
YES2GO 매출166보고값
주당순이익(EPS)$2.03+9% 전분기 대비
근거 있는 핵심 내용 6개
지금 중요한 점
이번 발표에서 가장 의미 있는 변화를 정리했습니다.
Demand
Yes2Go guidance raised to blockbuster $1 billion in first full year
HIV Treatment
BicLen FDA decision expected in August under priority review
핵심 내용 3개 더 보기
Oncology
Trodelvy first-line metastatic TNBC decisions expected in second half 2026
Cell Therapy
AnitoCell revenue expected to begin in early 2027
Cell Therapy
AnitoCell positioned as foundational multiple myeloma therapy
보고 기간
보고 실적
| 지표 | 보고값 | 변화 |
|---|---|---|
| HIV 매출 | $5B | 보고값 |
| 매출 | $6.96B | -12% 전분기 대비 |
| YES2GO 매출 | 166 | 보고값 |
| 주당순이익(EPS) | $2.03 | +9% 전분기 대비 |
| 매출총이익률 | 79.24% | 보고값 |
| 영업이익률 | 37.16% | 보고값 |
향후 전망
향후 가이던스
| 지표 | 기간 | 범위 | 중간값 | 상태 |
|---|---|---|---|---|
| 주당순이익(EPS) | FY2026 | $-1.05–$-0.65컨센서스 부합 | $-0.85 | 유지 |
| 매출HIV | FY2026 | $1B컨센서스 상회 | $1B | 상향 |
| 매출 | FY2026 | $30B–$30.4B컨센서스 부합 | $30.2B | 상향 |
AI, 자본지출 및 수요 분석
경영진 분석
Confident
Management repeatedly highlighted execution strength, raised product sales guidance, and framed upcoming decisions and launches as growth catalysts.
아래에 언급된 기업 3개 모두 표시
기업발표 이후 수익률
파트너
파트너
Dietmar Berger
Gilead's pending acquisition of Oral Medicines includes a licensing deal with Galapagos for gamgertamig, highlighting a deepening partnership.
근거
“we expect to develop in collaboration with Galapagos”
파트너
Dietmar Berger
Gilead is shifting its commercial strategy in HIV treatment by actively marketing a new brand (BicLen) that will cannibalize its flagship Biktarvy, aiming to capture patients who would otherwise switch to competitors. — This is a defensive launch to protect market share; while it may cannibalize Biktarvy, it is expected to keep higher-value patients within Gilead's portfolio.
근거
“we continue to target updates from the Phase 3 Island 1 and 2 trials in collaboration with Merck later this quarter.”
투자 대상
ARCLX
투자 대상
Daniel O'Day
The completed acquisition is expected to be a major growth driver for Gilead's cell therapy business, with the anito-cel CAR-T targeted for a late-December PDUFA.
근거
“Our acquisition of Arcelix, which closed on April 28th, reflects our conviction in the potential of a needle cell as a differentiated option for patients with multiple myeloma.”
외부 신호
공급망 알파 · 3발표 이후 수익률
The $1 billion full-year 2026 Yes2Go sales target implies a doubling from the current annualized run rate (Q1: $166M, up 72% sequentially) and likely assumes a very high persistency rate, a key risk if real-world adherence is lower than expected.
근거
“Given the outperformance of Yes2Go in the first quarter and our growing confidence in the trends we're seeing, we're increasing our 2026 Yes2Go guidance to $1 billion, potentially achieving blockbuster status in its first full year.”
Gilead is shifting its commercial strategy in HIV treatment by actively marketing a new brand (BicLen) that will cannibalize its flagship Biktarvy, aiming to capture patients who would otherwise switch to competitors.
근거
“We believe with Biclen, there's an opportunity to play in that switch market, which we haven't had in the past, and move them from Bicarbine, if they're going to switch anyway, to Biclen.”
The company is investing heavily in direct-to-consumer marketing for Yes2Go, which is a significant shift in strategy for a disease where outdated stigma has historically been a barrier to PrEP adoption.
근거
“Our DTC started late February, and what we've been seeing is a huge increase in brand awareness and visibility”
방법론 및 범위
경영진 발언만 분석합니다. 검증된 기업 언급 3개를 모두 표시하며, 보고 실적과 향후 가이던스를 분리합니다. 공개 근거는 화자가 표시된 짧은 인용문 8개로 제한됩니다. AI 분석은 불완전하거나 틀릴 수 있으므로 중요한 주장은 원문에서 확인하세요.